istock-635475308-1-

CIPhotos / iStockphoto.com

15 February 2018Americas

BMS pays $1.85bn for immuno-oncology programme

Bristol-Myers Squibb (BMS) has agreed to pay $1.85 billion for an immuno-oncology programme.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

BMS partners with drug accelerator to launch biotech

5 February 2020 Bristol-Myers Squibb and BioMotiv, a drug development accelerator, have launched Anteros Pharmaceuticals, a biotech focused on developing a new class of drugs for fibrotic and other inflammatory diseases.

Bristol-Myers Squibb to acquire Celgene in $74bn deal

3 January 2019 American pharmaceutical company Bristol-Myers Squibb has announced it is purchasing drug manufacturer Celgene in a $74 billion deal.

Roche to make $1.9bn acquisition

19 February 2018 Switzerland-based Roche has revealed plans to acquire a healthcare technology company for $1.9 billion.

More on this story

BMS partners with drug accelerator to launch biotech

5 February 2020 Bristol-Myers Squibb and BioMotiv, a drug development accelerator, have launched Anteros Pharmaceuticals, a biotech focused on developing a new class of drugs for fibrotic and other inflammatory diseases.

Bristol-Myers Squibb to acquire Celgene in $74bn deal

3 January 2019 American pharmaceutical company Bristol-Myers Squibb has announced it is purchasing drug manufacturer Celgene in a $74 billion deal.

Roche to make $1.9bn acquisition

19 February 2018 Switzerland-based Roche has revealed plans to acquire a healthcare technology company for $1.9 billion.

More on this story

BMS partners with drug accelerator to launch biotech

5 February 2020 Bristol-Myers Squibb and BioMotiv, a drug development accelerator, have launched Anteros Pharmaceuticals, a biotech focused on developing a new class of drugs for fibrotic and other inflammatory diseases.

Bristol-Myers Squibb to acquire Celgene in $74bn deal

3 January 2019 American pharmaceutical company Bristol-Myers Squibb has announced it is purchasing drug manufacturer Celgene in a $74 billion deal.

Roche to make $1.9bn acquisition

19 February 2018 Switzerland-based Roche has revealed plans to acquire a healthcare technology company for $1.9 billion.

More features

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB